Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Suspended 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1

Conditions

Neoplasms 18Leukemia, Myeloid, Acute 15Breast Neoplasms 14Glioblastoma 13Colorectal Neoplasms 13Prostatic Neoplasms 11Neoplasm Metastasis 10Carcinoma, Non-Small-Cell Lung 10Pancreatic Neoplasms 9Lung Neoplasms 9Glioma 8Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Myelodysplastic Syndromes 7Multiple Myeloma 7Head and Neck Neoplasms 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 7Hematologic Neoplasms 6Triple Negative Breast Neoplasms 5Rectal Neoplasms 5Ovarian Neoplasms 5Melanoma 5Uterine Cervical Neoplasms 4Colonic Neoplasms 4Brain Neoplasms 4Solid Tumor 3Small Cell Lung Carcinoma 3Sarcoma 3Recurrence 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3

Interventions

pembrolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Dendritic Cell Sarcoma, Follicular × 1 year × Clear all
NCT03316573 2026-02-10

Pembrolizumab in Neoplasms or Lymphomas

Dana-Farber Cancer Institute

Phase 2 Suspended
18 enrolled 16 charts
LymphoidSarcoma

Lymphoma, Dendritic Cell Sarcoma, Interdigitating, Dendritic Cell Sarcoma, Follicular, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡